SCHEMBL24843751

SCHEMBL24843751

SSCC1CNC1c1ccccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTH P32929 1/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
KDM4E B2RXH2 8/20 0.33
MAPT P10636 6/20 0.33
ALDH1A1 P00352 5/20 0.33
KMT2A Q03164 4/20 0.33
MEN1 O00255 2/20 0.33
MDM2 Q00987 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
TDP1 Q9NUW8 2/20 0.32
GSK3B P49841 1/20 0.31
POLB P06746 2/20 0.31
LMNA P02545 1/20 0.31
CYP1A2 P05177 1/20 0.31
CCR1 P32246 1/20 0.31
CCR5 P51681 1/20 0.31
CCR8 P51685 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25489368 0.76 PRCP (0.34) CTHDDB1CRBNKDM4EMAPT
SCHEMBL30000102 0.70 MAPT (0.42) CTHDDB1CRBNKDM4EMAPT
SCHEMBL28864035 0.69 DDB1 (0.37) CTHDDB1CRBNKDM4EMAPT
SCHEMBL27513865 0.68 MAPT (0.38) DDB1CRBNKDM4EMAPTALDH1A1
SCHEMBL13197255 0.66 KDM4E (0.48) CTHDDB1CRBNKDM4EMAPT
SCHEMBL203150 0.65 DDB1 (0.37) CTHDDB1CRBNKDM4EMAPT
SCHEMBL27793415 0.62 NISCH (0.40) DDB1CRBNKDM4EMAPTALDH1A1
SCHEMBL27793412 0.62 DDB1 (0.37) CTHDDB1CRBNKDM4EMAPT
SCHEMBL7897281 0.62 CHRNB4 (0.45) CTHDDB1CRBNKDM4EMAPT
SCHEMBL9372641 0.62 ALDH1A1 (0.42) CTHDDB1CRBNKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 CTH 258/4885DDB1 678/4885CRBN 1264/4885
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 CTH 258/4885DDB1 678/4885CRBN 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.